Bristol-Myers recalls vials of cancer drug

(AP)—Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.

The company's action affects 10 lots of BiCNU, an injection of the drug carmustine, used to treat , multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma.

Bristol-Myers said taking too much of the drug could result in lung or kidney toxicity, though no adverse events have been reported yet.

The drug was manufactured by Ben Venue Laboratories, a former manufacturing contractor for the New York drugmaker. The recall affects products sold in the U.S., Canada, Europe, Latin America and Asia.

Bristol-Myers said the recall is unlikely to result in a product shortage.

and customers can get more information by calling 1-888-896-4564.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

23 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments